Ultra Market Research | United States Migraine Market
United States Migraine Market
Report ID : 1080
Category : United-States(US)
No Of Pages : 134
Published on: April 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United States Migraine Market
Introduction
The US migraine market includes the development, approval, and sale of drugs intended to treat and prevent migraines, a neurological disorder characterized by frequent, disabling headache with or without nausea, vomiting, and photo- and phonosensitivity. Current trends reflect a profound movement towards biologic therapies, specifically CGRP (calcitonin gene-related peptide) inhibitors, that have shown effectiveness in both the acute and preventive treatment of migraines. The market value was around USD 2.09 billion in 2023 and is expected to achieve USD 4.66 billion by 2030 with a compound annual growth rate (CAGR) of 12.1% from 2024 to 2030 citeturn0search0. The growth is based on rising prevalence of migraines, technology advancements in treatment, and an increased awareness level among healthcare professionals and patients.
GlaxoSmithKline (UK) Pfizer Inc. (USA) AbbVie Inc. (USA) Amgen Inc. (USA) Eli Lilly and Co. (USA) Teva Pharmaceutical Industries Ltd. (Israel) Biohaven Ltd. (USA) Johnson & Johnson (USA) Bausch Health Companies Inc. (Canada) Axsome Therapeutics (USA) Novartis AG (Switzerland) Merck & Co. (USA) Allergan (USA) Zogenix (USA) Alder BioPharmaceuticals (USA)
Drivers
The United States migraine market is driven by a number of factors, such as the high incidence of migraines with around 12% of the population being affected. Improved treatment options, specifically the discovery of CGRP inhibitors like Aimovig, Ajovy, and Vyepti, have offered effective substitutes for conventional therapies citeturn0news13. Furthermore, rising awareness and enhanced diagnostic methods have resulted in improved detection and treatment of migraine patients. The increase in telehealth services and direct-to-consumer platforms, like Pfizer's Zavzpret, have also increased patient access to treatments citeturn0news14 In addition, the increased awareness of the economic and social burden of migraines has triggered investment in research and development, driving market growth.
Restraints
In spite of its expansion, the US migraine market has issues, such as the prohibitive price of new products, which can restrict patient access and insurance coverage. Stigma towards migraine as a valid medical illness can cause underdiagnosis and undertreatment. Racial inequities in access to healthcare and treatment outcomes are also challenges to the market environment, with disadvantaged communities receiving inferior care citeturn0news22. Moreover, regulatory challenges and the requirement of long periods of clinical testing before new drugs can be licensed can slow new therapies reaching the marketplace.
Opportunity
The U.S. migraine market offers many opportunities, especially in the creation of personalized medicine and combination therapies that are tailored to the needs of individual patients. The growing use of digital health solutions, such as mobile apps for symptom monitoring and virtual consultations, provides new opportunities for patient management and engagement. Increasing access to treatments through insurance reforms and patient assistance programs can increase market penetration. In addition, bridging healthcare disparities and providing equal access to treatment has the potential to unlock untapped population segments, fueling market growth.
Trend
One of the trends in the U.S. migraine market is the increasing tendency towards the use of CGRP inhibitors as initial-line treatments to replace traditional medicines such as antidepressants and beta-blockers. These biologic drugs provide site-specific action with enhanced efficacy and less side effects citeturn0news13. The approval of combination therapies like Axsome Therapeutics' Symbravo, which is a combination of meloxicam and rizatriptan, indicates a tendency towards multi-spectrum treatment strategy citeturn0news21. Also, the integration of telemedicine platforms for prescription and management is revolutionizing patient convenience and access, in line with wider healthcare digitalization trends.
Pharmaceutical Companies Healthcare Providers (Neurologists, General Practitioners) Insurance Providers Regulatory Bodies (FDA, CDC) Research Institutions Telehealth Platforms Patients and Patient Advocacy Groups Market Research Firms Investors and Venture Capitalists Healthcare Policy Makers
The United States migraine market was valued at approximately USD 2.09 billion in 2023 and is projected to grow significantly, reaching around USD 4.66 billion by 2030.
Key drivers include rising migraine prevalence, advancements in CGRP-based therapies, growing awareness, telehealth adoption, and increased R&D investment in migraine-specific treatments.
Acute treatment, particularly oral and injectable CGRP inhibitors, currently dominates the market due to their high efficacy and patient preference
Major restraints include high treatment costs, insurance coverage limitations, racial healthcare disparities, and regulatory hurdles for new drug approvals.
Key companies include Pfizer Inc., Amgen Inc., AbbVie, Eli Lilly, Biohaven, Teva Pharmaceuticals, and Novartis, among others.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Treatment Types 3.2.2 By Patient Demographics 3.2.3 By Distribution Channels 3.2.4 By Therapeutic Applications 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges
5. United States Migraine Therapeutics Market by Patient Demographics 5.1 Introduction 5.2 Market Size and Growth Rate by Patient Demographics (2024–2030) 5.2.1 Children 5.2.1.1 Infants 5.2.1.2 Toddlers and Young Children 5.2.2 Adults 5.2.2.1 Young Adults 5.2.2.2 Seniors
6. United States Migraine Therapeutics Market by Distribution Channels 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channels (2024–2030) 6.2.1 Hospital Pharmacies 6.2.1.1 Neurology Specialty Centers 6.2.1.2 Emergency Departments 6.2.2 Retail Pharmacies 6.2.2.1 Local Pharmacies 6.2.2.2 Chain Pharmacies 6.2.3 Online Pharmacies
7. United States Migraine Therapeutics Market by Therapeutic Applications 7.1 Introduction 7.2 Market Size and Growth Rate by Therapeutic Applications (2024–2030) 7.2.1 First-Line Treatments 7.2.1.1 Acute Medications 7.2.1.2 Preventive Therapies 7.2.2 Chronic Migraine Management 7.2.2.1 Long-Term Preventive Therapies 7.2.2.2 Lifestyle and Complementary Approaches 7.2.3 Refractory Migraine 7.2.3.1 Emerging Biologic Therapies 7.2.3.2 Experimental Neuromodulation
8. Competitive Landscape 8.1 Company Profiles 8.1.1 Amgen Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.2 Eli Lilly and Company (United States) 8.1.3 AbbVie Inc. (United States) 8.1.4 Pfizer Inc. (United States) 8.1.5 Teva Pharmaceuticals (Israel/US) 8.1.6 Lundbeck (Denmark) 8.1.7 Biohaven Pharmaceuticals (United States) 8.1.8 Novartis AG (Switzerland) 8.1.9 Sanofi (France) 8.1.10 GlaxoSmithKline (United Kingdom) 8.1.11 Allergan (an AbbVie Company, United States) 8.1.12 Dr. Reddy’s Laboratories (India/US) 8.1.13 Zosano Pharma (United States) 8.1.14 Axsome Therapeutics (United States) 8.1.15 Impel Pharmaceuticals (United States)
9. Conclusion and Strategic Recommendations
10. Appendix
10.1 List of Tables - Table United States Migraine Therapeutics Market Size by Treatment Types (2024–2030) - Table Acute Migraine Treatment Market Size by Sub-type (2024–2030) - Table Preventive Treatment Market Size by Sub-type (2024–2030) - Table Non-Pharmacologic Therapy Market Size by Sub-type (2024–2030) - Table United States Migraine Therapeutics Market Size by Patient Demographics (2024–2030) - Table Children Market Size by Sub-type (2024–2030) - Table Adults Market Size by Sub-type (2024–2030) - Table United States Migraine Therapeutics Market Size by Distribution Channels (2024–2030) - Table Hospital Pharmacies Market Size by Sub-type (2024–2030) - Table Retail Pharmacies Market Size by Sub-type (2024–2030) - Table United States Migraine Therapeutics Market Size by Therapeutic Applications (2024–2030) - Table First-Line Treatment Market Size by Sub-type (2024–2030) - Table Chronic and Refractory Migraine Market Size by Sub-type (2024–2030) - Table Financial Overview of Key Companies
10.2 List of Figures - Figure United States Migraine Therapeutics Market Size and Growth Rate by Treatment Types (2024–2030) - Figure Acute Treatment Growth Rate by Sub-type (2024–2030) - Figure Preventive Treatment Growth Rate by Sub-type (2024–2030) - Figure United States Migraine Therapeutics Market Size and Growth Rate by Patient Demographics (2024–2030) - Figure Children Market Growth Rate by Sub-type (2024–2030) - Figure Adults Market Growth Rate by Sub-type (2024–2030) - Figure United States Migraine Therapeutics Market Size and Growth Rate by Distribution Channels (2024–2030) - Figure Hospital Pharmacies Market Growth Rate by Sub-type (2024–2030) - Figure Retail Pharmacies Market Growth Rate by Sub-type (2024–2030) - Figure United States Migraine Therapeutics Market Size and Growth Rate by Therapeutic Applications (2024–2030)
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Malan overgrowth syndrome Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of CANOMAD syndrome Market for the past year and forecasts for the next six years. Malan overgrowth syndrome Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Malan overgrowth syndrome Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Malan overgrowth syndrome Market from different application industries in different regions.
